



150 W 4th Ave  
Vancouver, BC V5Y 1G6  
**T 1. 604.559.9005**  
**abcellera.com**

## NEWS RELEASE

# AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

2025-04-03

VANCOUVER, British Columbia--(BUSINESS WIRE)-- **AbCellera** (Nasdaq: ABCL) will announce its first quarter 2025 financial results on Thursday, May 8, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

A live audio webcast of the earnings conference may be accessed through a link that will be posted on **AbCellera's Investor Relations website**. A replay will be available through the same link following the conference call.

About AbCellera Biologics Inc.

**AbCellera** (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit **www.abcellera.com**.

Media: Tiffany Chiu; **media@abcellera.com**, +1(236)521-6774

Business Development: Murray McCutcheon, Ph.D.; **bd@abcellera.com**, +1(604)559-9005

Investor Relations: Peter Ahn; **ir@abcellera.com**, +1(778)729-9116

Source: AbCellera Biologics Inc.